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CD38 levels are elevated in regulatory T cells versus conventional T cells in MM patients

INTRODUCTION
Monoclonal antibodies (mAbs) targeting SLAMF7 and CD38 have become available to treat relapsed/refractory (RR) multiple myeloma (MM). Specifically, the first CD38 mAb daratumumab was approved in 2015 to treat RR MM (1) and is effective as a monotherapy (2, 3) .
Isatuximab (Isa)/SAR650984 (4), another therapeutic CD38 mAb currently under clinical development, also shows significant clinical activity in heavily pretreated patients with RR MM, both as a monotherapy and combined with Lenalidomide (Len)/Dexamethasone (Dex) (5) . In addition to Fc-dependent cytotoxicity mediated by IgG 1 -based CD38 mAbs, Isa induces direct killing of p53-mutated MM cells expressing high levels of CD38 in ex vivo cultures without effector cells and Fc cross-linking reagents (6) . Isa significantly kills CD38 high -expressing MM cells via induction of homotypic aggregation, leakage of lysosome-associated cathepsin B and lysosomal associated membrane protein-1 (LAMP-1), and generation of reactive oxygen species (6) . Furthermore, apoptosis is significantly enhanced when Isa is combined with Pomalidomide (Pom)/Len (6) . Since CD38 is widely expressed on hematopoietic cells, it is important to study whether Isa also has impact on these cells. To date, the effects of Isa on CD38-expressing immune cells and modulation of immune function is not defined.
Regulatory T cells (Tregs) play a crucial role in immune surveillance by suppressing activation, expansion, and function of target cells including CD4+CD25-conventional T cells (Tcons), cytotoxic CD8+ T cells, as well as Natural Killer (NK) cells (7) . They inhibit both cellular and humoral immune responses (8, 9) . Two forms of Tregs, "natural" and "induced" have been reported (10,11). Naturally occurring Tregs (nTregs), which constitute 5%-10% CD4+ lymphocytes, originate in the thymus and disseminate to periphery. Induced Tregs (iTregs) are generated in the periphery by soluble cytokines and cell-cell contact (10-12).
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Author Manuscript Published OnlineFirst on March 1, 2017; DOI: 10.1158/1078-0432.CCR- In parallel, tumor cells have the capacity to avoid immune recognition, to induce immune cell dysfunction, and to escape from immune surveillance via Tregs (9,13). The proportions of Tregs are elevated in the circulation of patients with solid tumors and hematologic malignancies (14) (15) (16) (17) (18) (19) . Increasing levels of Tregs often correlate with tumor burden and disease progression (16, (19) (20) (21) (22) . Accumulation of Treg in the tumor microenvironment is associated with reduced survival (15, 17, 18, 23) . Moreover, anti-tumor immune responses are enhanced in animal models after Treg depletion using mAbs against surface markers highly expressed on Tregs, i.e., CD25 (24) , CTLA-4 and OX40 (25) (26) (27) , and in transgenic DEREG mice (28). Thus, Tregs present a promising therapeutic target to restore anti-tumor immune responses.
CD38 is expressed on several lineages of hematopoietic cells including Tregs, and its levels correlate with the suppressive function of Tregs. CD38-knockout mice present with a loss of Peripheral blood nuclear cells (PBMCs) were collected from fresh buffy coat of healthy donors and MM patients after informed consent, in accordance with the Declaration of Helsinki and under the auspices of a Dana-Farber Cancer Institute Institutional Review Board approved protocol. PBMC were expanded in complete culture medium with 20 IU/ml rIL2 (Miltenyi Biotec, Germany). Isatuximab and its F(ab)'2 fragments were obtained from Sanofi (Cambridge, MA) (4, 6) . Len/Pom were purchased from Selectchem, anti-PD1/PD-L1 mAb from Biolegend (San Diego, CA), and Mitomycin C from Sigma-Aldrich (St Louis, MO).
Proliferation assay for Tregs and Tcons
PBMCs from normal donors were pretreated with or without 1μM Len/Pom for 3d, stained by 5μM CFSE (Invitrogen), and then plated in the presence or absence of indicated doses of Isa. 
Phenotyping and FACS analyses
Antibodies used for flow cytometry were as follows: CD4- Pacific Blue, CD25-PE,   CD25-APC, CD127-FITC, Foxp3-PE, CD38-PE-Cy7, AnnexinV-PE, PD1-APC, CD8-FITC,   CTLA4-PE-Cy7, CD44-FITC, CD62L-FITC, ICOS-FITC, GITR-PE, OX40-FITC, CD138-FITC, PD-L1-PE, and their isotype-matched mAbs (all from Biolegend). Intracellular staining of Foxp3, CTLA4, GITR, and OX40 were performed after fixation and permeabilization using cytofix/cytoperm kit (BD Biosciences), according to manufacturer's protocol. Tregs were gated as CD4+CD25highFoxp3+ cells in CD4+ population and then sequential markers were assayed on Tregs, whereas CD4+CD25-cells were identified as Tcons. immunosuppressive activity compared with CD25high population (34) . To avoid the effect of permeabilization when apoptosis assay was performed, CD4+CD25highCD127low/-cells were identified as Tregs (35) . All flow cytometry was performed by BD FACS CantoII, and analyzed on FlowJo software version 10 (Treestar).
Cell purification and immunosuppressive function assay
Tregs were purified using CD4+CD25+ Regulatory T cell Isolation Kit (Miltenyi Biotec, Germany). The purity of isolated population was >95%. Tcons were used as target cells in Tcons alone were used as controls. Isa was added into co-cultures for 7d, followed by FACS analysis to determine frequency and phenotype of Tregs. Supernatants were also collected for cytokine assessment.
Statistical analyses
Results are shown as means ± SEM or ranges, as appropriate. The student's t test was used to compare 2 groups. One-way ANOVA test was used to compare 3 or more groups. Two-way ANOVA test was used when there were two variables. Statistical analyses were carried out with Prism software (GraphPad Software, Inc). P < 0.05 was determined to be statistically significant. 
Results
CD38 expression is higher on Tregs versus
CD38 expression on Tregs is upregulated by IMiDs
We next assessed the impact of Len/Pom on CD38 expression on viable Tregs. Low dose (1μM) len and pom significantly increase MFI of CD38 on Tregs after 3d and persisting until 10d; moreover, the higher percentage CD38+Tregs was maintained relative to control medium ( 
Isa decreases Treg frequencies and inhibits Treg-suppression of Tcon proliferation, which is enhanced by IMiDs
When PBMCs from normal donors (n=10) were treated with or without Isa (1μg/ml) for 3 days, the frequency of Tregs in CD4+ cells is reduced from 8.88±0.66% at baseline to 4.56±0.77% Figure 3D ).
Isa induces apoptosis and inhibits proliferation and migration of Tregs
We next evaluated mechanisms of Isa-induced cytotoxicities against Tregs. Isa (0.1 μg/ml) induces approximately 2-fold higher percentage annexin V+ Tregs than control media ( Figure   4A 
CD25+Tregs from CD25-Tcons was partially abrogated when Tcons were separated from tumor cells (40) , indicating a role for cell-cell contact.
Our data show that Isa prevents induction of iTregs by MM cells and bone marrow microenvironment cells, associated with reduced TGFβ and IL10 in the coculture supernatants.
Potential mechanisms whereby Isa attenuates iTregs generation include: (1) iTregs express higher levels of CD38 than nTregs, making them even more sensitive to Isa; and (2) 
